INTERSECT ENT, INC.

Intersect Ent, Inc. specializes in the manufacturing of pharmaceutical preparations, with demonstrated experience supporting federal health initiatives through precise formulation, production, and regulatory-compliant scaling of drug products. Their technical expertise lies in GMP-compliant manufacturing processes, batch documentation, quality control systems, and adherence to FDA and P.L. 2025 standards for pharmaceutical development and distribution. The company’s differentiation stems from its ability to deliver small-batch, high-integrity pharmaceutical outputs aligned with evolving public health mandates, particularly in controlled or specialized therapeutic areas requiring strict chain-of-custody and traceability protocols. The contractor maintains a focused relationship with the Department of Veterans Affairs, providing pharmaceutical manufacturing services that support veteran healthcare delivery systems. This engagement suggests a role in supplying specialized medications, potentially for chronic conditions, mental health, or post-service medical needs, under federal procurement frameworks that prioritize reliability, consistency, and compliance with VA formulary requirements. Their primary industry focus is pharmaceutical preparation manufacturing under NAICS 325412, placing them squarely within the federal supply chain for finished drug products—excluding bulk active ingredients or medical devices. This vertical specialization positions them as a niche provider for mission-critical, low-volume, high-compliance pharmaceutical outputs, often required for unique clinical protocols or emergency preparedness programs. Intersect Ent, Inc. is a small business structured as a 2L entity, headquartered in Menlo Park, California. While currently holding no formal government certifications, their operational footprint reflects a lean, technically precise manufacturing model optimized for federal procurement environments. Their geographic positioning in California’s biotech corridor suggests proximity to research institutions and supply chain partners, enhancing their capacity to respond to agile federal health requirements.